- Report
- May 2024
- 135 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- May 2024
- 128 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- May 2024
- 129 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- May 2024
- 138 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- May 2024
- 137 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- May 2024
- 135 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- May 2024
- 135 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- May 2024
- 132 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- May 2024
- 133 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- May 2024
- 129 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Clinical Trials
- December 2024
- 280 Pages
Global
From €4772EUR$5,000USD£3,998GBP
- Report
- May 2024
- 298 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Drug Pipelines
- March 2025
- 80 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Drug Pipelines
- March 2025
- 280 Pages
Global
From €2863EUR$3,000USD£2,399GBP
- Report
- January 2025
- 308 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Drug Pipelines
- August 2024
- 60 Pages
Global
From €1193EUR$1,250USD£1,000GBP
- Drug Pipelines
- July 2024
- 60 Pages
Global
From €1432EUR$1,500USD£1,199GBP
- Drug Pipelines
- July 2024
- 60 Pages
Global
From €1432EUR$1,500USD£1,199GBP
- Clinical Trials
- June 2024
- 180 Pages
Global
From €2386EUR$2,500USD£1,999GBP
- Report
- April 2024
- 143 Pages
Global
From €7587EUR$7,950USD£6,357GBP

Immune Checkpoint Inhibitor drugs are a type of immunotherapy used to treat immune disorders. They work by blocking proteins that act as “checkpoints” in the immune system, allowing the body to recognize and attack cancer cells. These drugs are used to treat a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. They are also used to treat autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease.
Immune Checkpoint Inhibitor drugs are a relatively new form of treatment, and the market is still in its early stages. However, the potential of these drugs has led to a surge in research and development, with many companies investing in the development of new drugs.
Some of the major companies in the Immune Checkpoint Inhibitor market include Bristol-Myers Squibb, Merck, AstraZeneca, Roche, and Novartis. Other companies such as Pfizer, AbbVie, and Johnson & Johnson are also involved in the development of these drugs. Show Less Read more